Dapagliflozin Is A New Drug For The Treatment Of Type Two Diabetes

Dapagliflozin Is A New Drug For The Treatment Of Type Two Diabetes.


A late drug, the foremost in its class, gives added blood sugar be in control to people with type 2 diabetes who are already taking the glucose-lowering medication metformin. The unheard of agent, dapagliflozin, which also helped patients lose weight, is novel in that it does not work immediately on the body's insulin mechanisms, according to a study appearing in the June 26 issue of The Lancet and slated for spectacle at the annual meeting of the American Diabetes Association (ADA) in Orlando read full article. "It will doubtlessly be used as an add-on therapy," said study lead author Clifford Bailey, a chemical pathologist and professor of clinical knowledge at Aston University in Birmingham, UK "If you don't from head to toe get to target with the first therapy tried, this approach would offer you an opportunity it is hoped to maintain improved control".



Bailey, who could not predict if or when the drug might get final approval from drug regulatory authorities, also incisive out that dapagliflozin is flexible, meaning it can be used with various other treatments and at more or less any stage in the disease. "It's a high-minded add-on," agreed Dr Stanley Mirsky, associate clinical professor of metabolic diseases at Mount Sinai Medical Center in New York City continued. "is it a marvel drug? no. It may compete with a small role".



The study was funded by Bristol-Myers Squibb and AstraZeneca, which are developing dapagliflozin together. Dapagliflozin factory by stimulating the kidneys to eliminate more glucose from the body via urine. In this office of 534 adult patients with type 2 diabetes who were already taking metformin, the highest quantity of dapagliflozin (10 milligrams daily) was associated with a 0,84 percent easing in HbA1c levels.



HbA1c is a measure of blood sugar control over time. Participants taking 5 mg of the medicine saw a 0,70 percent decrease in HbA1c levels, while those taking 2.5 mg had a 0,67 percent decrease. In the placebo group, the shrivel in HbA1c was 0,3 percent, the exploration found.



Weight loss was also greater in volunteers taking the study drug: 2,2 kilograms (4,8 pounds) in the 2,5 mg group; 3 kilograms (6,6 pounds) in the 5 mg group; and 2,9 kilograms (6,4 pounds) in the 10 mg group. Those in the placebo company desperate 0,9 kilograms, or almost 2 pounds. Much, though not all, of this reduction was likely to be bottled water weight, the authors stated.



There were more genital infections seen among those taking dapagliflozin, the team noted. "One of the complications of the anaesthetize is an increase in urinary tract infections or yeast infections because you have high glucose levels in the urine," said Dr Jacob Warman, primary of endocrinology at The Brooklyn Hospital Center in New York City. "That's a very ample culture medium for yeast, so the endocrinologists aren't too elated about that".



On the other hand this drug appears to work without some of the kidney, liver and muscle complications of other drugs so "it would be cool as an add-on to usual medications". A second study, also simultaneously being presented at the ADA engagement and published in The Lancet, found that adding inhaled insulin before each refection and long-acting insulin glargine before going to bed worked just as well as taking conventional therapy.



The legitimate therapy consisted of taking biaspart insulin twice a day. This is a combination of short-acting insulin and intermediate-acting insulin. The creative regimen involved less weight gain, fewer episodes of quiet blood sugar and was more convenient, according to the study, which was funded by MannKind, the maker of Technosphere, the inhaled insulin featured in the trial.



A third boning up found that once-weekly injections of the drug Byetta (exenatide) worked better at controlling blood sugar levels than long-acting insulin. The pursuit thus far has been to give Byetta twice a day. This study, funded by Amylin Pharmaceueticals and Eli Lilly, looked at a renewed formulation of the drug resources. Patients who got the once-a-week blank also lost an average of 2,6 kilograms (5,7 pounds), the think over found.

tag : insulin dapagliflozin study pounds kilograms therapy levels hba1c percent

Post a comment

Private comment

Профиль

alejandrafalto

Author:alejandrafalto
Dr. Alejandra Falto

Новые записи
Новые комментарии
Новые трэкбэки
Архив по месяцам
Категории
Форма поиска
RSS ссылка
Ссылки
Формуляр приглашения в блог-друзья

Добавить автора в блог-друзья